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Background: This post-hoc analysis examined the impact of roflumilast on chronic obstructive
pulmonary disease (COPD) exacerbations and lung function in patients with COPD who received
concomitant long-acting b2-agonists (LABA) with or without prior inhaled corticosteroid (ICS)
and the influence of various demographic and clinical characteristics on these outcomes.
Methods: Data were pooled from 2 double-blind, placebo-controlled, 52-week studies of once-
daily roflumilast 500 mg in patients with COPD. Endpoints were mean rate of exacerbations and
change from baseline in pre- and postbronchodilator FEV1.
Results: In this pooled analysis (N Z 3091), addition of roflumilast to LABAs for 1 year in pa-
tients who discontinued ICS prior to study entry (n Z 945) significantly reduced the risk of
COPD exacerbations vs. placebo by 19.2% (p < 0.05) and significantly improved pre- and post-
bronchodilator FEV1 by 40 mL and 34 mL, respectively (both, p < 0.01). Similar improvements
were observed in patients who received concomitant LABAs but were not taking ICS prior to
study entry (n Z 597). A significant reduction in COPD exacerbation risk with roflumilast vs.
placebo was observed regardless of age or smoking status, and in patients who had severe
or very severe COPD. Significantly improved lung function was observed with roflumilast in
all the subgroups (p < 0.05), with the exception of patients with moderate COPD.ge of Medicine, One Baylor Plaza e BCM621, Houston, TX 77030, USA. Tel.: þ1 713 798 2347; fax: þ1
(N.A. Hanania).
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Pooled subpopulation analyses of roflumilast in COPD 367Conclusions: Roflumilast reduced exacerbation rates and improved lung function in patients
with COPD who received concomitant LABA, regardless of prior ICS use, and across various pa-
tient subgroups regardless of age and smoking status.
ClinicalTrials.gov registration numbers: NCT00297102 (M2-124) and NCT00297115 (M2-125).
ª 2013 Published by Elsevier Ltd.Introduction
Recent updates to the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) recommendations have
identified evaluation of exacerbation risk as a key compo-
nent of effective disease management [1]. Severe and/or
frequent exacerbations are associated with an accelerated
decline in lung function and worsening of health status,
contributing to increased hospitalization rates and health-
care utilization and expenditure [1e7]. Prevention and
reduction of the frequency of COPD exacerbations are
important therapeutic goals in COPD management [1]
Treatments with long-acting inhaled bronchodilators, with
or without inhaled corticosteroids (ICS), or with a
phosphodiesterase-4 (PDE4) inhibitor are interventions that
reduce the number of exacerbations and hospitalizations [1].
Roflumilast is an oral, once-daily, selective PDE4 inhibitor
which reduces the risk of exacerbations in patients with
severe COPD associated with chronic bronchitis and a history
of exacerbations [9e11]. Two 12-month studies (M2-124/M2-
125) demonstrated that compared with placebo, roflumilast
reduced exacerbation rates and improved lung function in
patients at risk for future exacerbations [10], independent
of concomitant long-acting b2-agonist (LABA) treatment [9].
Approximately 50% (1542/3091) of the patients in the
roflumilast pivotal studies received concomitant LABA during
the double-blind treatment period. Of these patients, 61%
(945/1542) had been treated with ICS, which was dis-
continued upon initiation of study treatment [10].
Although ICS is an effective treatment option in COPD
[1], concerns have arisen about their long-term use,
including an increased risk of pneumonia, bone fractures
[12], and adrenal insufficiency [13]. While stopping ICS
treatment may alleviate such concerns, 1-year ICS with-
drawal from an ICS/LABA treatment regimen has been
shown to result in increased risk of exacerbations and a
decline in pulmonary function in patients with COPD [14].
Hence it is important to know if using roflumilast with
concurrent LABA treatment can mitigate the expected in-
crease in COPD exacerbations and diminished lung function
resulting from ICS withdrawal. Furthermore, COPD is a
heterogeneous disease with chronic bronchitis [15], history
of exacerbations [8], age [5,16], smoking status [17,18],
and COPD severity [5,19,20] as factors that may contribute
to an increased risk of occurrence of COPD exacerbations.
Due to differential access to healthcare and/or exposure to
COPD risk factors [21], geographic differences may also
result in disparities in exacerbation risk, further contrib-
uting to the diverse epidemiology of the disease. It is also
important to know if the positive treatment benefit previ-
ously associated with roflumilast [10] is modulated by these
factors.In this post-hoc analysis of two pooled roflumilast
studies, we examined the efficacy outcomes in patients
randomized to roflumilast or placebo who received
concomitant LABA treatment with or without ICS treatment
prior to entry in the studies. Additionally we assessed the
influence of the patients’ age, smoking status, baseline
COPD disease severity, and geographic region on exacer-
bation rates and lung function.Methods
Study design
This pooled analysis included data from two identically
designed, multicenter, placebo-controlled, double-blind
studies with once-daily roflumilast 500 mg in patients with
COPD (M2-124 [NCT00297102] and M2-125 [NCT00297115]).
The methods have been previously published in detail, as
have the main results [10]. In brief, key inclusion criteria
consisted of the following: 40 years of age, smoking his-
tory 20 pack-years, clinical diagnosis of COPD (confirmed
with a postbronchodilator forced expiratory volume in
1 s [FEV1]/forced vital capacity [FVC] ratio 70%), chronic
cough and sputum production, and postbronchodilator FEV1
50% of predicted value. All patients had 1 recorded
COPD exacerbation requiring systemic glucocorticosteroids
or treatment in a hospital, or both, in the previous year.
Key exclusion criteria included unresolved COPD exacer-
bation within 4 weeks prior to baseline, asthma or other
relevant lung disease, cardiopulmonary or laboratory ab-
normalities, gastrointestinal disorders, HIV or hepatitis
infection, cancer within last 5 years, a1-antitrypsin defi-
ciency, and positive stool occult blood test at baseline. The
protocol was approved by the local ethics committees and
all patients provided written informed consent.
Each trial had a 4-week run-in period during which pa-
tients took once-daily oral placebo followed by randomi-
zation (1:1) to once-daily oral roflumilast 500 mg or placebo
taken in the morning for 52 weeks. Long-acting anticho-
linergic drugs and ICS were not allowed during the study.
Patients who received LABAs, fixed combinations of LABA
and ICS, tiotropium, or sequential tiotropium/LABA for 12
months prior to the study were allowed to continue LABA
treatment only at appropriate stable doses during the
study. Short-acting anticholinergics at appropriate stable
doses were also allowed.
The primary endpoints were the mean rate of exacer-
bations (per patient/year), defined as moderate if they
required oral or parenteral corticosteroids or severe if they
were associated with hospitalization or leading to death,
and the change from baseline in prebronchodilator FEV1
368 N.A. Hanania et al.during treatment. A key secondary outcome included
change from baseline in postbronchodilator FEV1.
Statistical analyses
Subgroup analyses were conducted using data from patients
in the intent-to-treat (ITT) population, defined as all ran-
domized patients from the two roflumilast studies taking at
least one dose of study drug after randomization. Patients
receiving concomitant LABA (salmeterol or formoterol)
during the studies were classified into two subgroups: those
who had received ICS prior to entering the study (þpre-ICS/
þLABA) and those who had not received ICS pretreatment
(pre-ICS/þLABA).
Analyses were also performed on several other pre-
defined subgroups: age (65 or >65 years); smoking status
(current or former smoker [cessation 1 year]); and base-
line COPD disease severity by postbronchodilator FEV1
(moderate [50% and <80% of predicted], severe [30%
and <50% of predicted], or very severe [<30% of pre-
dicted]). Subgroups were also defined by geographic region
as follows: North America (Canada, United States), Europe
(Austria, France, Germany, Hungary, Italy, Poland,
Romania, Russia, Spain, United Kingdom), or rest of the
world ([ROW], Australia, India, New Zealand, South Africa).
Estimated mean rates of moderate or severe COPD ex-
acerbations per patient/year were based on a Poisson
regression model. Changes from baseline in pre- and post-
bronchodilator FEV1 were analyzed using a repeated-
measures analysis of covariance (ANCOVA) [22]. For the
ITT population and all subgroups, Poisson regression and
ANCOVA analyses included the following factors: treat-
ment, study, age, sex, smoking status (except in smoking
status subgroups), and concomitant LABA (except in pre-
ICS/þLABA subgroups). All Poisson analyses also included
baseline FEV1 (% predicted) as a covariate and logarithm of
treatment duration as an offset, and all ANCOVA analyses
also included terms for baseline value, time (as a cate-
gorical variable), and treatment-by-time interaction. The
variance in Poisson analyses was adjusted using Pearson
Chi-Square statistics.
Results
Patients
As reported previously, the two studies had similar patient
baseline characteristics between roflumilast 500 mg
(nZ 1537) and placebo (nZ 1554) [10]. Baseline subgroup
data are presented in Table 1. Of the 3091 patients
included in this pooled analysis, 945 (30.6%) were pre-
treated with ICS and received concomitant LABA during the
randomized treatment period; an additional 597 (19.3%)
patients also received concomitant LABA but were not
pretreated with ICS. The average number of COPD exac-
erbations in the 12-month period prior to study entry was
1.43 for the þpre-ICS/þLABA group and 1.42 for the pre-
ICS/þLABA group; the proportion of patients with 1 or 2
prior exacerbations was also similar between these sub-
groups (þpre-ICS/þLABA, 69% and 21%, respectively; pre-
ICS/þLABA, 69% and 22%, respectively). Mean ages ofpatients were 57.3 and 72.4 years in the 65 years and >65
subgroups, respectively.
The smoking status subgroups comprised 1278 (41.3%)
current smokers and 1813 (58.7%) former smokers. Although
the inclusion criterion for these studies specified a post-
bronchodilator FEV1 50%, the threshold for severe COPD,
some patients who met this inclusion criterion at screening
but classified as mild and moderate COPD based on FEV1 at
randomization participated in the studies and were
included in the analyses. In the pooled population pre-
sented here, the COPD severity subgroups had 250 (8.1%),
1932 (62.5%), and 903 (29.2%) patients with moderate, se-
vere, and very severe COPD, respectively; due to small
sample size, 6 patients with mild COPD at baseline were not
included in these subgroup analyses. In the geographic re-
gion subgroups, 786 (25.4%) and 1831 (59.2%) patients were
from North America and Europe, respectively; 474 (15.3%)
were from the ROW. Within each subgroup, patients
treated with roflumilast and those receiving placebo had
similar baseline characteristics (data not shown). A few
notable differences were found across the COPD severity
and geographic region subgroups. The European subgroup
had fewer patients with very severe COPD (24.8%) than the
other subgroups (North America, 34.0%; ROW, 38.2%), as
well as more patients with prior ICS treatment (47.1%) than
the other subgroups (North America, 38.8%, ROW, 29.5%).Rate of exacerbations
After 52 weeks of treatment, roflumilast was associated
with fewer moderate or severe exacerbations than placebo
in all of the analyzed subgroups except those with
moderate severity of COPD (Figs. 1 and 2). Among placebo-
treated patients receiving concomitant LABA during the
two studies, a higher mean rate of exacerbations was
observed in those who discontinued ICS prior to entering
the study (þpre-ICS/þLABA; 1.67 per patient/year)
compared with those who did not receive ICS pretreatment
(pre-ICS/þLABA; 1.38 per patient/year). Among
roflumilast-treated patients, a reduction in exacerbation
rates compared with placebo occurred regardless of ICS
pretreatment (þpre-ICS/þLABA, 19.2%; pre-ICS/
þLABA, 24.0%; p < 0.05).
The small increase in the exacerbation rate observed
with ICS discontinuation was mitigated by roflumilast
treatment, as demonstrated by the lower exacerbation rate
in the roflumilast þpre-ICS/þLABA group of 1.34 per pa-
tient/year, a significant 19.2% reduction compared with
placebo (þpre-ICS/þLABA, 1.67 per patient/year; risk ratio
[RR] Z 0.81; 95% confidence interval [CI] 0.68, 0.96;
p Z 0.015). Similarly, patients treated with concomitant
LABA without prior ICS experienced a 24.0% reduction in
exacerbation rate, a significant difference between treat-
ment arms, in favor of roflumilast (RRZ 0.76; 95% CI 0.60,
0.96; p Z 0.022).
In patients who were 65 years or >65 years of age,
treatment with roflumilast compared with placebo resulted
in significant reductions in exacerbations in both age groups
(15.3% and 21.2%, respectively; both subgroups, p < 0.05
vs. placebo). Roflumilast also provided superior control of
exacerbations than placebo regardless of smoking status,
Table 1 Demographics and baseline characteristics in patient subgroups.
Pretreatment/
concomitant treatment
Age Smoking status COPD severity Geographic region
þICS/þ
LABA
n Z 945
ICS/þ
LABA
n Z 597
65 years
n Z 1761
>65 years
n Z 1330
Current
n Z 1278
Former
n Z 1813
Moderate
n Z 250
Severe
n Z 1932
Very
severe
n Z 903
North
America
n Z 786
Europe
n Z 1831
Rest of
world
n Z 474
Age, mean
years (SD)
64.6 (9.1) 64.2 (9.1) 57.3 (5.8) 72.4 (4.8) 60.4 (8.4) 66.2 (9.0) 62.4 (9.6) 64.4 (9.3) 63.0 (8.7) 64.9 (9.0) 63.9 (9.2) 61.3 (9.1)
Male, n (%) 696 (73.7) 453 (75.9) 1245 (70.7) 1091 (82.0) 887 (69.4) 1449 (79.9) 159 (63.6) 1425 (73.8) 748 (82.8) 480 (61.1) 1425 (77.8) 431 (90.9)
Race, n (%)
Asian 38 (4.0) 16 (2.7) 246 (14.0) 109 (8.2) 107 (8.4) 248 (13.7) 25 (10.0) 191 (9.9) 136 (15.1) 5 (0.6) 3 (0.2) 347 (73.2)
Black 7 (0.7) 12 (2.0) 30 (1.7) 18 (1.4) 20 (1.6) 28 (1.5) 5 (2.0) 32 (1.7) 11 (1.2) 46 (5.9) 2 (0.1) 0 (0.0)
White 874 (92.5) 559 (93.6) 1415 (80.4) 1181 (88.8) 1119 (87.6) 1477 (81.5) 214 (85.6) 1652 (85.5) 727 (80.5) 725 (92.2) 1791 (97.8) 80 (16.9)
Other 26 (2.8) 10 (1.7) 70 (4.0) 22 (1.7) 32 (2.5) 60 (3.3) 6 (2.4) 57 (3.0) 29 (3.2) 10 (1.3) 35 (1.9) 47 (9.9)
Smoking status, n (%)
Current 344 (36.4) 236 (39.5) 928 (52.7) 350 (26.3) 1278 (100.0) 0 (0.0) 126 (50.4) 826 (42.8) 323 (35.8) 349 (44.4) 781 (42.7) 148 (31.2)
Former 601 (63.6) 361 (60.5) 833 (47.3) 980 (73.7) 0 (0.0) 1813 (100.0) 124 (49.6) 1106 (57.2) 580 (64.2) 437 (55.6) 1050 (57.3) 326 (68.8)
COPD severity,
n (%)
Mild 0 (0.0) 0 (0.0) 4 (0.2) 2 (0.2) 3 (0.2) 3 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.2) 3 (0.6)
Moderate 69 (7.3) 35 (5.9) 155 (8.8) 95 (7.1) 126 (9.9) 124 (6.8) 250 (100.0) 0 (0.0) 0 (0.0) 68 (8.7) 151 (8.2) 31 (6.5)
Severe 602 (63.7) 379 (63.5) 1040 (59.1) 892 (67.1) 826 (64.6) 1106 (61.0) 0 (0.0) 1932 (100.0) 0 (0.0) 451 (57.4) 1222 (66.7) 259 (54.6)
Very severe 274 (29.0) 183 (30.7) 562 (31.9) 341 (25.6) 323 (25.3) 580 (32.0) 0 (0.0) 0 (0.0) 903 (100.0) 267 (34.0) 455 (24.8) 181 (38.2)
Lung function, mean (SD)
Prebronchodilator
FEV1, L
1.02 (0.36) 1.01 (0.35) 1.04 (0.39) 0.97 (0.33) 1.07 (0.37) 0.97 (0.35) 1.50 (0.39) 1.09 (0.29) 0.70 (0.20) 0.92 (0.36) 1.08 (0.35) 0.93 (0.38)
Postbronchodilator
FEV1, L
1.10 (0.38) 1.08 (0.36) 1.14 (0.40) 1.06 (0.34) 1.16 (0.39) 1.07 (0.37) 1.67 (0.40) 1.20 (0.29) 0.75 (0.18) 1.03 (0.36) 1.16 (0.37) 1.05 (0.40)
Prebronchodilator
FEV1,
% predicted
33.6 (9.8) 32.8 (9.7) 32.8 (10.8) 33.7 (9.9) 34.5 (10.7) 32.3 (10.2) 50.4 (8.7) 35.9 (6.6) 22.3 (5.3) 31.4 (11.2) 34.7 (9.6) 30.2 (11.0)
Postbronchodilator
FEV1,
% predicted
36.2 (10.2) 35.3 (9.9) 35.9 (11.1) 36.7 (10.1) 37.4 (10.8) 35.4 (10.5) 55.9 (5.3) 39.3 (5.5) 23.8 (4.3) 35.0 (10.9) 37.3 (10.1) 34.1 (11.9)
Concomitant
treatment
with LABA, n (%)
945 (100.0) 597 (100.0) 847 (48.1) 695 (52.3) 580 (45.4) 962 (53.1) 104 (41.6) 981 (50.8) 457 (50.6) 338 (43.0) 1125 (61.4) 79 (16.7)
Pretreatment
with ICS, n (%)
945 (100.0) 0 (0.0) 724 (41.1) 583 (43.8) 482 (37.7) 825 (45.5) 95 (38.0) 838 (43.4) 373 (41.3) 305 (38.8) 862 (47.1) 140 (29.5)
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; LABA, long-acting b2-agonist; SD, standard deviation.
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Figure 1 Mean rate of moderate or severe COPD exacerbations per patient/year in the ITT population and subpopulations. COPD,
chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; ITT, intent to treat; LABA, long-acting b2-agonist; D indicates %
change from placebo Z (rate ratio  1)*100.
370 N.A. Hanania et al.with similar percent reductions relative to placebo found in
current and former smokers (17.7% and 18.4%, respectively;
both subgroups, p < 0.05 vs. placebo). Treatment with
roflumilast relative to placebo significantly reduced exac-
erbation rates by 18.7% and 19.7% in the severe and very
severe COPD groups, respectively (both subgroups, p < 0.05
vs. placebo). In patients with moderate COPD, exacerba-
tion rates were <1 per patient/year in both treatment
groups, but no significant differences between treatment
groups were observed. This lack of statistical significance in
the moderate COPD subgroup may have been due in part to
both the low frequency of COPD exacerbations reported in
these studies for this subgroup, as well as its small patient
number, resulting in a wide confidence interval in its rate
ratio vs. placebo. Analyses of mean exacerbation rates
favored roflumilast over placebo in all geographic region
subgroups, with exacerbations significantly reduced in pa-
tients from North America and ROW (21.7% and 25.8%,
respectively; both subgroups, p < 0.05 vs. placebo).Lung function
Both pre- and postbronchodilator FEV1 significantly
improved with roflumilast compared with placebo
(p < 0.01), irrespective of previous ICS use in patients
receiving concomitant LABA (Figs. 3 and 4). Similar to the
positive impact of roflumilast on exacerbation rates, lung
function was also improved with roflumilast regardless of
geographic region, age, or smoking status (Figs. 3 and 4).
Lung function was significantly improved with roflumilast
compared with placebo in patients with severe or very
severe COPD; however, no statistically significant
between-treatment-group differences in patients with
moderate COPD were demonstrated. Similar to the results
on the rate of exacerbations, this lack of statistical sig-
nificance in lung function in the moderate COPD subgroup
may have been due in part to its smaller patient number,
resulting in wider confidence intervals for treatmentdifferences vs. placebo compared with those of other
subgroups of greater COPD severity.Discussion
In this pooled analysis of two 52-week randomized,
placebo-controlled, double-blind studies, the addition of
roflumilast to LABA therapy for one year in patients who
discontinued ICS prior to study entry significantly reduced
the risk of COPD exacerbations and improved lung function.
These results extend previous analyses of these studies,
which demonstrated a similar treatment benefit of roflu-
milast in patients who received concomitant LABA treat-
ment [9]. Replacement of ICS with roflumilast may thus be
able to minimize the previously reported disease deterio-
ration that is expected with ICS discontinuation from an
ICS/LABA treatment regimen [14]. Although the exact
mechanism of such an effect needs further exploration, our
findings suggest that even though the mechanism of action
by which roflumilast reduces airway inflammation [23,24] is
different from that of an ICS [25,26], it may be able to
prevent the rebound increase in exacerbation rate and thus
the disease deterioration observed with ICS withdrawal.
Roflumilast also significantly reduced the rate of COPD ex-
acerbations in patients with concomitant LABA treatment
but who did not receive ICS prior to study entry (pre-ICS/
þLABA), demonstrating a reduced risk of COPD exacerba-
tions with roflumilast regardless of prior ICS treatment.
It is worth noting that patients who discontinued ICS in
these studies, in either the placebo or roflumilast groups,
had a higher rate of COPD exacerbations compared with
those who did not receive prior ICS treatment, similar to
the slightly increased COPD exacerbation rate observed in a
previous study of ICS withdrawal [14]. This result may
reflect the possibility that patients who initially received
ICS treatment may have been at greater risk for COPD ex-
acerbations compared with those who did not receive
previous ICS treatment. Risk of COPD exacerbations may be
Figure 2 Rate ratios and 95% confidence intervals for reduction of moderate or severe COPD exacerbations in the ITT population
and subpopulations. COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; ITT, intent to treat; LABA, long-
acting b2-agonist.
Pooled subpopulation analyses of roflumilast in COPD 371assessed using both COPD exacerbation history and severity
of airflow obstruction. As the average frequency of COPD
exacerbations prior to entering the studies for þpre-ICS/
þLABA and pre-ICS/þLABA was similar for both sub-
groups, the differences in COPD exacerbation rates
observed between these subgroups during the studies are
not likely due to patients’ exacerbation history. Further-
more, lung function values at baseline were also compa-
rable between these subgroups. It is possible that prior ICS
treatment may have masked a difference in lung function
at baseline between patients in the þpre-ICS/þLABA and
pre-ICS/þLABA subgroups that could have contributed to
the higher rate of exacerbations observed in patients who
discontinued ICS during these studies. In addition, switch-
ing from ICS/LABA to LABA monotherapy in the þpre-ICS/
þLABA group compared with the absence of a similar
change in treatment regimen in the pre-ICS/þLABA group
may have also played a role in the difference in exacer-
bation rates observed in these studies. However, switching
from one inhaled therapy to another suggests that the
impact of such a change would be minimal.
Although roflumilast has no direct bronchodilator activ-
ity, the improvement in pulmonary function observed here
with roflumilast may also be due to its effects on sup-
pressing airway inflammation. Other studies have reported
similar improvements in lung function in patients treated
with roflumilast either alone [11,27,28] or in combination
with long-acting bronchodilators [29]. Roflumilast may
therefore be considered an effective alternative to ICS for
patients currently taking LABAs who are at risk for
exacerbations.This pooled analysis of the two roflumilast studies also
generally demonstrated a treatment benefit with roflumi-
last vs. placebo across all subgroups defined by age (65
years, >65 years), smoking status (current smokers, former
smokers), COPD severity (moderate, severe, very severe),
and geographic region (North America, Europe, ROW). As
expected, the effects of roflumilast vs. placebo on reducing
exacerbation rates were comparable in the subgroups of
patients with severe COPD (RR Z 0.81) and very severe
COPD (RRZ 0.80), supporting the recommended use of this
medication for the management of exacerbations in severe
COPD patients [30]. As the subgroup of patients with
moderate COPD had fewer subjects (130 subjects for
either roflumilast or placebo) and lower COPD exacerbation
rates during the studies (<1 per patient/year) compared
with the other subgroups of greater COPD severity, there
may have been insufficient data to appropriately evaluate
the impact of roflumilast in this COPD subgroup.
Significant mean improvements in pre- and post-
bronchodilator FEV1 were found with roflumilast in pa-
tients regardless of age, smoking status, or geographic
region. Roflumilast also reduced exacerbations in these
subgroups, although this did not reach statistical signifi-
cance in the European subgroup (p Z 0.073). This may be
due to the slightly healthier population of patients from
Europe compared with those from other regions, as evi-
denced by the higher FEV1 at baseline and lower propor-
tion of patients with very severe COPD in Europe vs. North
America or the ROW. Furthermore, among placebo-
treated patients in different geographic regions, the
lowest COPD exacerbation rate was reported in Europe.
Figure 3 Mean change from baseline in (A) pre- and (B) postbronchodilator FEV1 at Week 52 for placebo and roflumilast in the ITT
population and subpopulations. COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; ITT, intent to treat;
LABA, long-acting b2-agonist. D indicates treatment difference from placebo.
372 N.A. Hanania et al.This may reflect regional differences in treatment prac-
tice, as demonstrated by the highest rate of prior ICS use
in the European subgroup (47.1%) compared with the
North American or ROW subgroups (38.8% or 29.5%,
respectively). In addition, since exacerbations were
defined based on healthcare utilization, differences in
access to healthcare resources between the different
geographic regions [21] may have also contributed to the
lower rate of COPD exacerbations in Europe. Other factors
that might have contributed to regional differences in
exacerbation rates include the presence of comorbidities
[5], number of prior hospitalizations [5,17], effects of
seasonal changes [31], air quality [32], and genetic vari-
ations [33e35]. However, without further analyses of
these and other potential factors, no definitive explana-
tion can be given for the statistically nonsignificant
reduction on exacerbation rate in the European subgroup
observed with roflumilast treatment.The major limitations of the roflumilast studies have
been addressed in the primary report [10]. As was dis-
cussed, no conclusions can be drawn regarding the synergy
or interaction between ICS and LABA with added roflumi-
last, since patients were required to discontinue ICS
treatment prior to study entry. However, the current
pooled analyses do indicate that roflumilast added to LABA
is effective regardless of prior ICS treatment. It was also
noted in the primary report that, in accordance with good
clinical trial practice, recruitment for these 52-week
studies focused on patients who were likely to adhere to
treatment, and the results may not be generalizable to the
general clinic population. This limitation also applies to the
current pooled analysis, although these findings confirm
that many subgroups of patients with severe COPD and
history of exacerbations may benefit from roflumilast
treatment, regardless of concomitant LABAs. Finally,
although most of the subgroups in this report were defined
Figure 4 Least squares (LS) mean differences between roflumilast and placebo in (A) pre- and (B) postbronchodilator FEV1 in the
ITT population and subpopulations. COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; ICS,
inhaled corticosteroid; ITT, intent to treat; LABA, long-acting b2-agonist.
Pooled subpopulation analyses of roflumilast in COPD 373a priori, analyses of these subgroups were intended to
be exploratory in nature. Thus, although this pooled anal-
ysis indicates treatment effects with roflumilast across
different patient subpopulations, the results presented
above should be interpreted with some caution.Conclusions
Results from this pooled analysis of two randomized,
placebo-controlled, double-blind, 52-week studies,
demonstrated that roflumilast compared with placebo
374 N.A. Hanania et al.significantly reduced exacerbation rates and improved lung
function in patients with severe or very severe COPD who
received concomitant LABA, regardless of prior ICS treat-
ment. In addition to confirming the efficacy of roflumilast in
patients with severe or very severe COPD, this analysis
confirmed the benefits of treatment across various sub-
groups regardless of age and smoking status.
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